238 related articles for article (PubMed ID: 19567518)
1. Increased 5 alpha-reductase activity and adrenocortical drive in women with polycystic ovary syndrome.
Vassiliadi DA; Barber TM; Hughes BA; McCarthy MI; Wass JA; Franks S; Nightingale P; Tomlinson JW; Arlt W; Stewart PM
J Clin Endocrinol Metab; 2009 Sep; 94(9):3558-66. PubMed ID: 19567518
[TBL] [Abstract][Full Text] [Related]
2. Altered cortisol metabolism in polycystic ovary syndrome: insulin enhances 5alpha-reduction but not the elevated adrenal steroid production rates.
Tsilchorozidou T; Honour JW; Conway GS
J Clin Endocrinol Metab; 2003 Dec; 88(12):5907-13. PubMed ID: 14671189
[TBL] [Abstract][Full Text] [Related]
3. Beyond adrenal and ovarian androgen generation: Increased peripheral 5 alpha-reductase activity in women with polycystic ovary syndrome.
Fassnacht M; Schlenz N; Schneider SB; Wudy SA; Allolio B; Arlt W
J Clin Endocrinol Metab; 2003 Jun; 88(6):2760-6. PubMed ID: 12788885
[TBL] [Abstract][Full Text] [Related]
4. Adrenal androgen excess and body mass index in polycystic ovary syndrome.
Moran C; Arriaga M; Arechavaleta-Velasco F; Moran S
J Clin Endocrinol Metab; 2015 Mar; 100(3):942-50. PubMed ID: 25514100
[TBL] [Abstract][Full Text] [Related]
5. Hyperandrogenism in polycystic ovary syndrome. Evidence of dysregulation of 11 beta-hydroxysteroid dehydrogenase.
Rodin A; Thakkar H; Taylor N; Clayton R
N Engl J Med; 1994 Feb; 330(7):460-5. PubMed ID: 8289851
[TBL] [Abstract][Full Text] [Related]
6. Hyperandrogenism in women with polycystic ovary syndrome persists after menopause.
Markopoulos MC; Rizos D; Valsamakis G; Deligeoroglou E; Grigoriou O; Chrousos GP; Creatsas G; Mastorakos G
J Clin Endocrinol Metab; 2011 Mar; 96(3):623-31. PubMed ID: 21177795
[TBL] [Abstract][Full Text] [Related]
7. Prolactin is associated with metabolic risk and cortisol in 1007 women with polycystic ovary syndrome.
Glintborg D; Altinok M; Mumm H; Buch K; Ravn P; Andersen M
Hum Reprod; 2014 Aug; 29(8):1773-9. PubMed ID: 24903198
[TBL] [Abstract][Full Text] [Related]
8. Increased clearance of cortisol by 5beta-reductase in a subgroup of women with adrenal hyperandrogenism in polycystic ovary syndrome.
Gambineri A; Forlani G; Munarini A; Tomassoni F; Cognigni GE; Ciampaglia W; Pagotto U; Walker BR; Pasquali R
J Endocrinol Invest; 2009 Mar; 32(3):210-8. PubMed ID: 19542736
[TBL] [Abstract][Full Text] [Related]
9. Influence of adrenal hyperandrogenism on the clinical and metabolic phenotype of women with polycystic ovary syndrome.
Alpañés M; Luque-Ramírez M; Martínez-García MÁ; Fernández-Durán E; Álvarez-Blasco F; Escobar-Morreale HF
Fertil Steril; 2015 Mar; 103(3):795-801.e2. PubMed ID: 25585504
[TBL] [Abstract][Full Text] [Related]
10. Genetic variation in 11beta-hydroxysteroid dehydrogenase type 1 predicts adrenal hyperandrogenism among lean women with polycystic ovary syndrome.
Gambineri A; Vicennati V; Genghini S; Tomassoni F; Pagotto U; Pasquali R; Walker BR
J Clin Endocrinol Metab; 2006 Jun; 91(6):2295-302. PubMed ID: 16551740
[TBL] [Abstract][Full Text] [Related]
11. Myostatin and its association with abdominal obesity, androgen and follistatin levels in women with polycystic ovary syndrome.
Chen MJ; Han DS; Yang JH; Yang YS; Ho HN; Yang WS
Hum Reprod; 2012 Aug; 27(8):2476-83. PubMed ID: 22693174
[TBL] [Abstract][Full Text] [Related]
12. 5 alpha-reductase and 11 beta-hydroxysteroid dehydrogenase activity in prepubertal Hispanic girls with premature adrenarche.
Silfen ME; Shackleton CH; Manibo AM; Levine LS; Sekhar D; McMahon DJ; Oberfield SE
J Clin Endocrinol Metab; 2002 Oct; 87(10):4647-51. PubMed ID: 12364451
[TBL] [Abstract][Full Text] [Related]
13. Comparison of markers of insulin resistance and circulating androgens between women with polycystic ovary syndrome and women with metabolic syndrome.
Tziomalos K; Katsikis I; Papadakis E; Kandaraki EA; Macut D; Panidis D
Hum Reprod; 2013 Mar; 28(3):785-93. PubMed ID: 23315058
[TBL] [Abstract][Full Text] [Related]
14. Tissue-specific dysregulation of 11β-hydroxysteroid dehydrogenase type 1 in overweight/obese women with polycystic ovary syndrome compared with weight-matched controls.
Gambineri A; Fanelli F; Tomassoni F; Munarini A; Pagotto U; Andrew R; Walker BR; Pasquali R
Eur J Endocrinol; 2014 Jul; 171(1):47-57. PubMed ID: 24743397
[TBL] [Abstract][Full Text] [Related]
15. Altered composition of high density lipoproteins in women with the polycystic ovary syndrome.
Rajkhowa M; Neary RH; Kumpatla P; Game FL; Jones PW; Obhrai MS; Clayton RN
J Clin Endocrinol Metab; 1997 Oct; 82(10):3389-94. PubMed ID: 9329374
[TBL] [Abstract][Full Text] [Related]
16. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
17. Testosterone to dihydrotestosterone ratio as a new biomarker for an adverse metabolic phenotype in the polycystic ovary syndrome.
Münzker J; Hofer D; Trummer C; Ulbing M; Harger A; Pieber T; Owen L; Keevil B; Brabant G; Lerchbaum E; Obermayer-Pietsch B
J Clin Endocrinol Metab; 2015 Feb; 100(2):653-60. PubMed ID: 25387259
[TBL] [Abstract][Full Text] [Related]
18. Expression of 11beta-hydroxysteroid dehydrogenase 1 and 2 in subcutaneous adipose tissue of lean and obese women with and without polycystic ovary syndrome.
Svendsen PF; Madsbad S; Nilas L; Paulsen SK; Pedersen SB
Int J Obes (Lond); 2009 Nov; 33(11):1249-56. PubMed ID: 19704410
[TBL] [Abstract][Full Text] [Related]
19. Polycystic ovary syndrome and anti-Müllerian hormone: role of insulin resistance, androgens, obesity and gonadotrophins.
Cassar S; Teede HJ; Moran LJ; Joham AE; Harrison CL; Strauss BJ; Stepto NK
Clin Endocrinol (Oxf); 2014 Dec; 81(6):899-906. PubMed ID: 25040369
[TBL] [Abstract][Full Text] [Related]
20. Ovarian 11β-hydroxysteroid dehydrogenase (11βHSD) activity is suppressed in women with anovulatory polycystic ovary syndrome (PCOS): apparent role for ovarian androgens.
Michael AE; Glenn C; Wood PJ; Webb RJ; Pellatt L; Mason HD
J Clin Endocrinol Metab; 2013 Aug; 98(8):3375-83. PubMed ID: 23678035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
